Open Accessibility Menu

Coronavirus (COVID-19) Vaccine Update Click here to learn more.

For information about COVID-19 or to view additional resources, please click here.

  • Certified ALS Center Program
    Certified ALS Center Program
  • Level 4 Epilepsy Center - national association of epilepsy centers
    National Association of Epilepsy Centers
  • Comprehensive Stroke Center
  • AANEM EDX Lab Accreditation - exemplary status
    AANEM EDX Lab Accreditation

Rescue Room

Washington DC Migraine Treatment

Individuals who suffer an acute, severe migraine headache that persists despite self-administered therapy typically have one of two options: either seek care at an emergency room or simply “suffer in silence” until the headache attack eventually ends. The first option is time-consuming, often uncomfortable, costly and not necessarily guaranteed to result in an effective treatment outcome. The discomfort and disadvantages of “suffering in silence” speak for themselves.

Our headache “Rescue Room” offers a third and more attractive alternative. Patients who are actively being followed in The Headache Center and who are experiencing an acute, severe migraine headache that is not responding to self-administered therapy may call the Center Monday-Friday at (202) 677-6823 to request in-clinic treatment.

Treatment Options

Treatment typically involves intravenous hydration and subcutaneous, intramuscular or intravenous administration of a medication or a combination of medications known to be effective in the treatment of a persistent migraine attack. The “Rescue Room” is located within the headache clinic itself, and patients will be treated by providers who are familiar with them and with their headache management.

Note:

  • Acute headache sufferers seeking treatment in the “Rescue Room” should be established patients at The Headache Center who are actively being followed (“actively” implies a clinic visit within the previous 6 months).
  • Patients seeking treatment in the “Rescue Room” ideally should call early in the day to ensure that there is time for them to be evaluated and treated before the clinic’s closing time.
  • Patients may use the “Rescue Room” no more than two times within any 30 day period.
  • Patients presenting to the “Rescue Room” should bring a companion age 18 or older who is capable of transporting them home or to another secure location after treatment has been completed.
  • We do not treat patients with opiates/opioids (‘narcotics’) or other controlled substances in our “Rescue Room.”

Make an appointment with the Rescue Room at (202) 677-6823

Conveniently Located

Clinical Trials

  • Phase 3 ALS study (CY 5031) with reldesemtiv. (Cytokinetics)
    This is a Phase 3, double-blind, randomized, placebo-controlled trial of reldesemtiv in patients aged 18 to 80 with ALS to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS
  • Food as Medicine to Improve Lifestyle for Stroke Patients (FAMILY (CAFB))
    The purpose of this study is to evaluate if groceries delivered every two weeks, along with nutrition education and nutrition counseling, will improve the health of individuals who have recently had a stroke.
  • Sleep for Stroke Management And Recovery Trial (SleepSmart)
    Investigator-initiated, phase 3 multicenter, prospective randomized open-, blinded-endpoint (PROBE) controlled trial to test whether treatment of obstructive sleep apnea (OSA) with continuous positive airway pressure is effective for secondary prevention and recovery after stroke.
  • Preventative treatment of migraine: Outcomes for patients in realy-world healthcare systems (Triumph)
    This study is a 24-month prospective, multicenter, international, 2-stage noninterventional study reflecting treatment within real-world settings of patients with migraine who are switching or initiating pharmacologic treatment for migraine prevention
  • A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice (TV48125)
    A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice
  • A 12 month prospective, randomized, interventional, global, multicenter, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs oral prophylactics) in adult episodic migraine patients (AMG334A2401)
    This study uses a single-cohort, 2-treatment arm (erenumab versus oral SoC prophylactic treatment), parallel-group randomized (2:1 [erenumab (70mg or 140mg): SoC oral prophylactic]), open-label design in adult patients with episodic migraine who have previously failed 1 or 2 prophylactic migraine treatments.
  • A phase 4, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of erenumab in adults with chronic migraine and medication overuse headache (Amgen20170703)
    Study 20170703 is a phase 4, randomized, double-blind, double-dummy, parallel-group, placebo-controlled study to evaluate the safety and efficacy of erenumab against placebo in a CM population with MOH and prior history of treatment failure.
  • A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety and tolerability of atogepant for the prevention of chronic migraine (Allergan3101-303-002)
    Multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and tolerability of atogepant 30 mg twice per day (BID) and 60 mg once daily for the prevention of chronic migraine (CM).
  • A phase 2, randomized, placebo-controlled study to evaluate the safety, tolerability and efficacy of TAK-079 in patients with generalized myasthenia gravis (TAK079-1005)
    This is a phase 2, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of TAK-079 in patients with generalized MG in combination with standard background therapy.
  • A phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis (UCB MG0003)
    This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 3-arm, repeat dose study evaluating the efficacy and safety of two doses of rozanolixizumab and matching placebo in patients with generalized MG who experience moderate to severe symptoms (Myasthenia Gravis Foundation of America [MGFA II-IVa]) and are being considered for additional treatment such as IVIg or PEX
  • A phase II study to evaluate the safety and tolerability of pyridostigmine when given with ondansetron to subjets with anti-AChR postive myasthenia gravis (DAS-MG)
    This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis to compare the gastrointestinal (GI) side effects of pyridostigmine alone and when given with ondansetron in patients with a known diagnosis of anti-AchR antibody positive myasthenia gravis and current (i.e., past 7 days) pyridostigmine-related GI side effects
  • A phase 3, multicenter, open-label extension study of Zilucoplan in subjects with generalized myasthenia gravis (RA Pharma 302: Raise XT)
    Study RA101495-02.302 is a multicenter, open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study. The visit schedule during the first 12 weeks of Study RA101495-02.302 (RAISE)